Today: 19 January 2026
Subscribe
Browse Category

Clinical Trials News 17 September 2025 - 7 October 2025

Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Recent Stock Performance & Surge on Data Dyne Therapeutics’ stock has been on a tear following its latest clinical breakthroughs. Shares jumped 10–11% intraday on October 7, 2025, after the company reported positive one-year results from a key trial, lifting the stock to about $14.02 by mid-day Marketbeat Marketbeat. This rally builds on a strong upward trend in recent months…
7 October 2025
····
Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Trial Results: Big Early Losses, Then Weight Loss Levels Off This highly anticipated trial put Lilly’s oral GLP-1 drug, orforglipron, to the test in a large group of adults struggling with obesity. The study enrolled 3,127 overweight or obese participants (none had diabetes, but all had weight-related health issues) and randomly assigned them to various daily doses of the pill…
17 September 2025
·
1 … 6 7 8

Stock Market Today

  • Zacks Highlights Strong Stock Performers: Amicus, Micron, Amgen Amid Market Uncertainty
    January 19, 2026, 9:46 AM EST. Last week, the Dow, S&P 500, and Nasdaq closed down amid trade-war fears and tariff jitters that pushed investors toward safe havens like gold. Economic and central bank cues remain in focus, with trade negotiations expected to influence market direction. Against this backdrop, Zacks Investment Research spotlights outperforming stocks such as Amicus Therapeutics and Enhabit, which jumped 61.7% and 32.3% respectively following Zacks Rank upgrades. Zacks' equal-weight portfolio of Rank #1 (Strong Buy) stocks outperformed the S&P 500 by 7 percentage points over recent months and the past decade, showing the effectiveness of their stock-rating system. Additional upgraded stocks like Drilling Tools International and Kennametal gained over 20%, indicating strong momentum despite broader market pressures. Investors watch Zacks guidance amid ongoing economic uncertainty to better position portfolios.
Go toTop